The effect of cinromide on "kindled" seizures in the rat.
Cinromide, an experimental anticonvulsant (Burroughs Wellcome Co.) was tested against focal cortical (simple partial analog), focal amygdala (complex partial analog), and generalized convulsive (tonic-clonic analog) seizures in the "kindled" rat. The toxicity in the CNS was measured by the ataxia scale devised by Desmedt, Niemegeers, Lewi and Janssen (Arzneimittel-Forsch, 26: 1592-1602, 1976). Cinromide was found to suppress generalized convulsions in small, subtoxic doses, whereas larger, sometimes toxic doses were required to suppress focal seizure activity. The general pattern of response resembles that of the standard clinical anticonvulsants which the present authors have previously investigated. Cinromide, however, was relatively more potent against focal amygdala (complex partial analog) seizures than any drug previously tested, except carbamazepine. These data suggest that cinromide should be clinically effective, not only against tonic-clonic seizures, but also, toxicity permitting, against complex partial attacks as well.
D000818:Animals; D000927:Anticonvulsants / Q000627:therapeutic use*; D002934:Cinnamates / Q000627:therapeutic use* / Q000633:toxicity; D007696:Kindling, Neurologic; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D012640:Seizures / Q000188:drug therapy*
D000927:Anticonvulsants; D002934:Cinnamates; C018490:cinromide